Javascript must be enabled to continue!
Heart rate control and its relation to mortality in patients with chronic heart failure at Viet Tiep Friendship Hospital
View through CrossRef
Objectives: To evaluate the association between discharge heart rate and cardiovascular mortality within 6 months after discharge in patients with chronic heart failure. Methods: A prospective descriptive study was conducted on 105 patients with chronic heart failure treated at the Cardiology Department, Viet Tiep Friendship Hospital, from January 2024 to November 2025. Heart failure was diagnosed according to the 2021 ESC criteria. Patients were divided into two groups: discharge heart rate <70 bpm (n=42) and discharge heart rate ≥70 bpm (n=63). Baseline characteristics including age, sex, comorbidities, NYHA classification, and cardiovascular mortality within 6 months were recorded. Survival was analyzed using the Kaplan–Meier method and Cox regression model. Results: The mean age was 68.81 ± 12.1 years, with 47.62% aged ≥70 years. Females accounted for 50.48%. Most patients were classified as NYHA III–IV (77.28%). Common comorbidities included hypertension (60.95%), atrial fibrillation (29.52%), valvular heart disease (27.62%), and chronic kidney disease (21.9%). One-month mortality was 9.52% in the group with discharge heart rate ≥70 bpm versus 2.38% in the group with discharge heart rate <70 bpm (p>0.05). Six-month mortality was 3.17% in the ≥70 bpm group compared with 0% in the <70 bpm group. Kaplan–Meier analysis revealed a trend toward higher mortality in patients with discharge heart rate ≥70 bpm, although the difference was not statistically significant (HR=2.55; 95% CI: 0.71–9.13; p>0.05). Conclusion: A discharge heart rate ≥70 bpm is associated with a trend toward higher 6-month mortality in patients with chronic heart failure.
Hai Phong University of Medicine and Pharmacy
Title: Heart rate control and its relation to mortality in patients with chronic heart failure at Viet Tiep Friendship Hospital
Description:
Objectives: To evaluate the association between discharge heart rate and cardiovascular mortality within 6 months after discharge in patients with chronic heart failure.
Methods: A prospective descriptive study was conducted on 105 patients with chronic heart failure treated at the Cardiology Department, Viet Tiep Friendship Hospital, from January 2024 to November 2025.
Heart failure was diagnosed according to the 2021 ESC criteria.
Patients were divided into two groups: discharge heart rate <70 bpm (n=42) and discharge heart rate ≥70 bpm (n=63).
Baseline characteristics including age, sex, comorbidities, NYHA classification, and cardiovascular mortality within 6 months were recorded.
Survival was analyzed using the Kaplan–Meier method and Cox regression model.
Results: The mean age was 68.
81 ± 12.
1 years, with 47.
62% aged ≥70 years.
Females accounted for 50.
48%.
Most patients were classified as NYHA III–IV (77.
28%).
Common comorbidities included hypertension (60.
95%), atrial fibrillation (29.
52%), valvular heart disease (27.
62%), and chronic kidney disease (21.
9%).
One-month mortality was 9.
52% in the group with discharge heart rate ≥70 bpm versus 2.
38% in the group with discharge heart rate <70 bpm (p>0.
05).
Six-month mortality was 3.
17% in the ≥70 bpm group compared with 0% in the <70 bpm group.
Kaplan–Meier analysis revealed a trend toward higher mortality in patients with discharge heart rate ≥70 bpm, although the difference was not statistically significant (HR=2.
55; 95% CI: 0.
71–9.
13; p>0.
05).
Conclusion: A discharge heart rate ≥70 bpm is associated with a trend toward higher 6-month mortality in patients with chronic heart failure.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Giáo trình Giao tiếp Kinh doanh 2023
Giáo trình Giao tiếp Kinh doanh 2023
LỜI MỞ ĐẦUGiao tiếp hiệu quả phản ánh mức độ phức tạp của kinh doanh trong thời đại thông tin hiện nay. Thông tin đã trở nên thật cần thiết trong kinh doanh ngày nay. Hiện nay, nhi...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Giáo trình Giao Tiếp Kinh Doanh
Giáo trình Giao Tiếp Kinh Doanh
LỜI MỞ ĐẦUNhu cầu giao tiếp hiệu quả phản ánh mức độ phức tạp của kinh doanh trong thời đại thông tin hiện nay. Chẳng bao lâu trước đây, thông tin vẫn còn là thứ xa xỉ, nhưng ngày ...
Thông báo và thư mời đại hội tim mạch toàn quốc làn thứu 18 và lễ kỷ niệm 30 năm thành lập Hội Tim mạch học Việt Nam
Thông báo và thư mời đại hội tim mạch toàn quốc làn thứu 18 và lễ kỷ niệm 30 năm thành lập Hội Tim mạch học Việt Nam
THÔNG BÁO VÀ THƯ MỜI ĐẠI HỘI TIM MẠCH TOÀN QUỐC LẦN THỨ 18 VÀ LỄ KỶ NIỆM 30 NĂM THÀNH LẬP HỘI TIM MẠCH HỌC VIỆT NAM
(Thông báo số 1)
Hà Nội, ngày 15 tháng 03 năm 2022
Kính gửi: ...
HỆ QUI CHIẾU ĐƯỢC ĐỀ XUẤT CHO NGHIÊN CỨU TƯƠNG ĐỒNG-DỊ BIỆT TRONG GIAO TIẾP GIAO VĂN HOÁ VÀ SỰ CỐ DỤNG HỌC TRONG GIAO TIẾP LIÊN VĂN HOÁ: QUI CHIẾU TÁC ĐỘNG (GIAO TIẾP) (BÀI 3)
HỆ QUI CHIẾU ĐƯỢC ĐỀ XUẤT CHO NGHIÊN CỨU TƯƠNG ĐỒNG-DỊ BIỆT TRONG GIAO TIẾP GIAO VĂN HOÁ VÀ SỰ CỐ DỤNG HỌC TRONG GIAO TIẾP LIÊN VĂN HOÁ: QUI CHIẾU TÁC ĐỘNG (GIAO TIẾP) (BÀI 3)
Tiếp nối bài 1 và 2 tổng quan các cách tiếp cận khác nhau của các học giả khác nhau, đồng thời, đề xuất cách thức xem xét chiều qui chiếu ‘Biểu hiện’ (văn hoá) trong cách tiếp cận ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

